Physician profile
Lashanda Putman
NPI 1295234938
$2,211.97
in general payments reported to CMS, 2019-2025
10 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.30 · 2022: $571 · 2023: $896 · 2024: $261 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,419.97 |
| Education | $175.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $722.17 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $403.66 | 2022-2024 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $393.73 | 2021-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $232.32 | 2023 | |
| Vanda Pharmaceuticals INC. | $123.23 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $106.04 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $103.99 | 2023-2025 | Uzedy |
| Alkermes, INC. | $86.92 | 2022 | |
| Lundbeck LLC | $21.82 | 2023 | Rexulti |
| Novo Nordisk INC | $18.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lashanda Putman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.